Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them ...

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

A study has found that people with eczema are able to bathe either daily or weekly, without any impact on their symptoms.

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...